Compare WNW & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNW | DARE |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 21.6M |
| IPO Year | 2019 | 2014 |
| Metric | WNW | DARE |
|---|---|---|
| Price | $4.00 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 50.3M | 99.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $3,195.79 |
| Revenue Next Year | N/A | $95.92 |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.05 | $1.27 |
| 52 Week High | $13.52 | $9.19 |
| Indicator | WNW | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 82.54 | 60.15 |
| Support Level | $1.40 | $1.67 |
| Resistance Level | $13.52 | $1.80 |
| Average True Range (ATR) | 0.18 | 0.12 |
| MACD | 0.23 | 0.06 |
| Stochastic Oscillator | 72.95 | 78.38 |
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.